Our Proprietary Products Our commercial product portfolio reflects our years of experience in drug development and our patient- centered approach. Our medicines address patient needs in major disease areas. ARISTADA ® (aripiprazole lauroxil) extended-release is a injectable suspension long-acting atypical antipsychotic that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia. ARISTADA is available in four dose strengths with once-monthly dosing (441 mg, 662 mg, 882 mg), a six- week dosing option (882 mg) and a two-month dosing option (1064 mg). For important safety and full product information, please visit www.aristada.com. VIVITROL ® (naltrexone for extended-release injectable suspension) is a once-monthly, non-narcotic, injectable medication approved in the U.S., Russia and certain countries of the CIS for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support. For important safety and full product information, please visit www.vivitrol.com. WEBSITE www.alkermes.com TICKER SYMBOL Nasdaq: ALKS EMPLOYEES Approximately 2,000 WW CONTACTS Media Relations Voice: +1 781 609 6143 [email protected] Investor Relations Voice: +1 781 609 6143 [email protected] Blair Jackson Senior Vice President, Business Development Voice: +1 781 609 6594 About Us At Alkermes plc, our employees consistently strive to provide physicians and patients with treatment options that address important unmet needs. Through our scientific expertise, proprietary technologies and global resources, we are uniquely positioned to continue building a portfolio of medicines for major clinical conditions with a focus on central nervous system (CNS) disorders. Our success to date is evident from our diverse commercial product portfolio, including treatments in major diseases, such as schizophrenia and addiction. Beyond our commercial products, we have a promising pipeline of proprietary drug candidates, many in late-stage development. Both our commercialized products and rich pipeline demonstrate our leadership in drug development for CNS diseases, a therapeutic area where we have established expertise and a promise for delivering new treatments. A Perspective From our CEO, Richard Pops “This is an amazing company because we’re actually going after some of the most important diseases that affect mankind… where the burden of disease is still massive around the world…” Richard F. Pops Chairman and Chief Executive Officer Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis.